参考文献/References:
[1] Arkoumani M, Papadopoulou-Marketou N, Nicolaides NC,et al. The clinical impact of growth differentiation factor-15 in heart disease: a 2019 update[J]. Crit Rev Clin Lab Sci,2020,57(2)：114-125.
[2] Wang X, Baek SJ, Eling TE. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer[J]. Biochem Pharmacol,2013,85(5):597-606.
[3] Chung HK, Ryu D, Kim KS, et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis[J]. J Cell Biol ,2017,216(1):149-165.
[4] Shin MY, Kim JM, Kang YE,et al. Association between growth differentiation factor 15 (GDF15) and cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus[J]. J Korean Med Sci,2016,31(9):1413-1418.
[5] Xie S, Lu L, Liu L. Growth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality: a meta-analysis of prospective studies[J].Clin Cardiol,2019,42(5):513-523.
[6] Chugh SS,Havmoeller R,Narayanan K,et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study[J]. Circulation,2014,129(8):837-847.
[7] Lok SI,Winkens B,Goldschmeding R,et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support[J]. Eur J Heart Fail, 2012,14:1249-1256.
[8] Doulamis IP,Samanidis G,Tzani A,et al. Proteomic profile of patients with atrial fibrillation undergoing cardiac surgery[J]. Interact Cardiovasc Thorac Surg,2019,28(1):94-101.
[9] Lind L,Sundstrom J,Stenemo M,et al. Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip[J]. Heart, 2017,103(5):377-382.
[10] Hu XF, Zhan R, Xu S, et al. Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation[J]. Clin Cardiol, 2018, 41(1):34-38.
[11] Matusik PT, Ma?ecka B, Lelakowski J, et al. Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation[J]. Clin Res Cardiol,2020,109 (4):426-434.
[12] Hijazi Z,Oldgren J,Andersson U,et al. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation:insights from the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial[J]. Am Heart J, 2017,190:94-103.
[13] Bootcov MR,Bauskin AR,Valenzuela SM,et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-superfamily[J].Immunol Cell Biol,1997, 94:11514-11519.
[14] Yang H, Filipovic Z, Brown D, et al. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation[J]. Mol Cancer Ther, 2003, 2:1023-1029.
[15] Kelly JA,?Lucia MS, Lambert JR. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms[J]. Cancer Lett,2009,277(1):38-47.
[16] Cheung CL,Tan KCB,Au PCM,et al. Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human:a Mendelian randomization study[J]. EBioMedicine,2019,41:85-90.
[17] Bloch SA, Lee JY, Syburra T, et al. Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs[J]. Thorax,2015,70(3):219-228.
[18] Bouabdallaoui N, Claggett B, Zile MR, et al. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial[J]. Eur J Heart Fail, 2018,20(12):1701-1709.
[19] Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective[J]. J Diabetes Res,2015,2015:1-14.
[20] Li J, Yang L, Qin W, et al. Adaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus[J]. PLoS One, 2013,8(6):e65549.
[21] 刘洪梅,邵清淼,刘恩照,等.心房颤动患者血清生长分化因子-15检测及其临床意义[J]. 天津医药,2014,42(8):818-821.
[22] Shao Q, Liu H, Ng CY,et al. Circulating serum levels of growth differentiation factor-15 and neuregulin-1 in patients with paroxysmal non-valvular atrial fibrillation[J].Int J Cardiol,2014,172(2):e311-313.
[23] Zhou YM,Li MJ,Zhou YL,et al.Growth differentiation factor-15 (GDF-15), novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease[J]. Int J Clin Exp Med,2015,8(11):21201-21207.
[24] 曹哲哲,马瑞彦.心房颤动的心房纤维化分子机制研究进展[J].心血管病学进展,2019,40(3):359-362.
[25] Wallentin L,Hijazi Z,Andersson U,et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial[J]. Circulation,2014,130(21):1847-1858.
[26] Berg DD, Ruff CT, Jarolim P, et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48[J]. Circulation,2019,139(6):760-771.
[27] Rossaint J,Vestweber D,Zarbock A. GDF-15 prevents platelet integrin activation and thrombus formation[J]. J Thromb Haemost,2013,11(2):335-344.
[28] Hijazi Z, Oldgren J, Lindb?ck J,et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study[J]. Lancet,2016,387(10035):2302-2311.
[29] Sharma A, Hijazi Z, Andersson U, et al. Use of biomarkers to predict specific causes of death in patients with atrial fibrillation[J].Circulation,2018 , 138(16):1666-1676.
[30] Hijazi Z, Verdecchia P, Oldgren J, et al. Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RE-LY trial[J]. J Am Heart Assoc,2019,8(2):e010107.
[31] Santema BT, Chan MMY, Tromp J, et al. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure[J].Clin Res Cardiol, 2020,109(3):331-338.
[32] Hijazi Z, Oldgren J, Lindb?ck J, et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score[J]. Eur Heart J,2018,39(6):477-485.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(7):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(7):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(7):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(7):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(7):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(7):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
[12]王昱冕 陈涵 王红.生长分化因子15与心血管疾病出血事件相关性的研究进展[J].心血管病学进展,2022,(10):928.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.015]
WANG Yumian,CHEN Han.,WANG Hong.Relationship Between Growth Differentiation Factor 15 and Cardiovascular Bleeding Events[J].Advances in Cardiovascular Diseases,2022,(7):928.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.015]